Thousands with fatty liver disease monitored to understand long-term risks
NCT ID NCT04721665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study followed 1,681 people with steatotic liver disease (fatty liver) in Germany to observe how the condition progresses over time. Researchers measured liver stiffness, inflammation, and tracked whether participants developed heart problems or tumors. The goal was to better understand the natural course of the disease, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIM GmbH
Münster, Germany
-
Eugastro GmbH
Leipzig, Germany
-
Fachinternistische Schwerpunktpraxis
Hamburg, Germany
-
Gastroenterologische Studiengesellschaft Herne
Herne, Germany
-
Infektiologisches Zentrum Steglitz
Berlin, Germany
-
Leber- und Studienzentrum Checkpoint
Berlin, Germany
-
Leberstudienzentrum Kiel
Kiel, Germany
-
MVZ Dres. Eisenbach,Simon, Schwarz GbR
Leverkusen, Germany
-
MVZ Viszeralmedizin GmbH
Cologne, Germany
-
MVZ für Gastroenterologie am Bayerischen Platz
Berlin, Germany
-
Praxis Dr. med. Kerstin Stein
Magdeburg, Germany
-
Praxis Ludwig und Dikopoulos
Dornstadt, Germany
-
Praxis für Innere Medizin mit Schwerpunkt Gastroenterologie Dr. med. Jeannette Schwenzer
Berlin, Germany
-
St. Josefs-Hospital Medizinische Klinik II
Wiesbaden, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a probiotic supplement help reverse fatty liver?
- Simple blood test may spot hidden liver trouble in colitis patients
- AI spots hidden liver disease in routine scans
- 10,000 seniors studied to predict fatty liver dangers
- New drug tested in patients with fatty liver and cirrhosis
- New study aims to catch hidden liver disease in diabetes patients